Lumiracoxib

Publisher Website
Google Scholar
Abstract
▲ Lumiracoxib is a highly selective and potent cyclo-oxygenase (COX)-2 inhibitor, with a novel structure that conveys weakly acidic properties and a unique pharmacological profile. It is rapidly absorbed, with a relatively short plasma half-life. ▲ In well designed clinical trials of 1–52 weeks’ duration in patients with osteoarthritis (OA) or rheumatoid arthritis, the efficacy of oral lumiracoxib 100–400 mg/day in decreasing pain intensity and improving functional status was greater than that with placebo and similar to those with nonselective NSAIDs or celecoxib 200mg once daily. ▲ In single- and multiple-dose well designed trials in patients with acute pain associated with primary dysmenorrhoea, dental or orthopaedic surgery or tension-type headache, lumiracoxib 100–800mg once daily was more effective in relieving acute pain than placebo or controlled-release oxycodone 20mg, and was at least as effective as selective COX-2 inhibitors or nonselective NSAIDs. ▲ Lumiracoxib was generally well tolerated in clinical trials, with a similar overall tolerability profile to those of placebo and other COX-2-selective inhibitors. ▲ In a large 52-week safety trial in patients with OA, lumiracoxib 400mg once daily had a rate of gastrointestinal ulcer complications that was approximately one-third to one-quarter of that of ibuprofen 800mg three times daily or naproxen 500mg twice daily. Lumiracoxib was not associated with an increasein cardiovascular events.

This publication has 20 references indexed in Scilit: